KPW
CBIO

Kore Private Wealth’s Crescent Biopharma CBIO Stock Holding History

Kore Private Wealth’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10
Closed -$12K – 449
2019
Q1 		$12K Hold
10
– – ﹤0.01% 593
2018
Q4 		$9K Buy
+10
New +$12K ﹤0.01% 578

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Kore Private Wealth's CBIO Position: Q2 2019 in Review

Kore Private Wealth sold out of Crescent Biopharma (CBIO) in Q2 2019, closing a stake of 10 shares — an estimated $12K sold.

Kore Private Wealth first reported a position in CBIO in Q4 2018 and held it in 2 quarters. The position peaked at $12K in Q1 2019. 78 funds tracked by Wall St. Rank hold CBIO as of Q2 2019.

  • Kore Private Wealth reported no remaining Crescent Biopharma position as of Q2 2019 after selling out during the quarter.
  • Kore Private Wealth sold 10 Crescent Biopharma shares in Q2 2019, an estimated $12K.
  • Kore Private Wealth first reported a position in Crescent Biopharma in Q4 2018 and held it in 2 quarters.
  • Kore Private Wealth's Crescent Biopharma position peaked at $12K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2019.

Based on Kore Private Wealth's 13F filing for Q2 2019, filed 14 Aug 2019.